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Epidemiological evidence suggests that some, if
not all, environmentally relevant metals,
including arsenic (As), cadmium (Cd),
chromium (Cr), and lead (Pb), are human car-
cinogens. Unfortunately, human exposures to
such metals in both the occupational and envi-
ronmental setting are common occurrences. In
fact, because of high As (and other metal) con-
centrations in the drinking water supplies in
many countries, chronic toxicity and develop-
ment of neoplastic lesions have become health
problems of global proportions (1,2). In the
United States, As, Cd, Cr, and Pb are the top
four metals in site frequency count by the
Agency for Toxic Substances and Disease
Registry (ATSDR) Completed Exposure
Pathway Site Count Report (3); three of these,
As, Pb, and Cd, are among the Superfund’s
top 10 priority hazardous substances (4). In
addition, these metals most often occur
together; they are present in 8 of 10 and 5 of
10 of the top 10 binary combinations of cont-
aminants in soil and water, respectively (5).
The mechanisms mediating metal-induced
cytotoxicity and carcinogenicity are currently
unclear. Many laboratories, using a variety of
experimental systems, have carried out detailed
studies in attempts to address these issues.
From this work, it has become apparent that
metals affect multiple intracellular targets and
exert a variety of diverse effects on cells in vitro
(6,7). Studies suggest that different metals have
unique primary mechanisms of action that are
cell specific and/or tissue specific (6,7).
Additionally, the activity of a metal in any
given tissue is dependent on its speciation and
metabolism (6). To further complicate the pic-
ture, metals have been shown to interact at
multiple levels and, most likely, modify one
another’s cytotoxicity and/or carcinogenic
potential (8–11). As a result, we are still a long
way from a fundamental understanding of the
actions of metals or metal mixtures at the cel-
lular level, particularly as they relate to toxic
end points. Accurate risk assessment of these
highly relevant chemicals awaits our progress
in this area.
The skin is one important target organ for
As-mediated pathological effects and is a useful
model system for mechanistic studies in this
area. Chronic exposure to As leads to skin dis-
orders such as hyperkeratosis and, in many
cases, carcinogenesis (12,13). Both As and Cr,
a well-known skin sensitizer, have substantial
effects on epidermal keratinocytes in vitro and
in vivo; these metals have been shown to alter
expression of numerous growth regulatory
factors, to stimulate cell proliferation at low
concentrations, and to inhibit the normal
process of differentiation (11,14–19). They
have not, however, been shown to be directly
transforming in this cell type. In transgenic
Tg.AC mice, As acts as co-promoter during
skin carcinogenesis in standard two-stage mod-
els (20). These studies have suggested that
transforming growth factor-α (TGFα) and
granulocyte/macrophage-colony stimulating
factor may be useful biomarkers for As-associ-
ated carcinogenesis in keratinocytes; data from
As-exposed human subjects support this
hypothesis (20). It is likely, however, that the
picture is much more complex than this and
that the genes involved are more numerous.
New technologies in expression analysis at
the RNA and protein levels have led to the
development of the field of toxicogenomics,
that is, the use of genetic information to
address issues such as these that are crucial in
toxicology. As an approach to defining the
mechanism(s) behind selective chemical toxi-
city, one may analyze gene expression changes
in cells after exposure to the chemical(s) of
interest. Methodologies such as microarray
analysis allow one to gain a comprehensive
view of the cellular pathways affected by the
chemical(s) under scrutiny; comparison may
then be made between multiple chemicals
having the same or differing toxicities.
Characterization of the relationship among
chemical exposure, gene expression alter-
ations, and development of acute or chronic
toxicity should help in delineating important
molecular events that are mechanistically
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The identiﬁcation of molecular markers related to critical biological processes during carcinogene-
sis may aid in the evaluation of carcinogenic potentials of chemicals and chemical mixtures. Work
from our laboratory demonstrated that a single treatment with N-methyl-N´-nitro-N-
nitrosoguanidine (MNNG) enhanced spontaneous malignant transformation of the human ker-
atinocyte cell line RHEK-1. In contrast, chronic low-level exposure of cells to arsenic alone or in a
mixture containing arsenic, cadmium, chromium, and lead inhibited malignant conversion. To
identify changes in gene expression that influence these different outcomes, cDNA microarray
technology was used. Analysis of multiple human arrays in MNNG-transformed RHEK-1 cells,
designated OM3, and those treated with arsenic or the arsenic-containing metal mixture showed
unique patterns of gene expression. Genes that were overexpressed in OM3 included oncogenes,
cell cycle regulators, and those involved in signal transduction, whereas genes for DNA repair
enzymes and inhibitors of transformation and metastasis were suppressed. In arsenic-treated cells,
multiple DNA repair proteins were overexpressed. Mixture-treated cells showed increased expres-
sion of a variety of genes including metallothioneins and integrin β4. These cells showed
decreased expression of oncogenes, DNA repair proteins, and genes involved in the mitogen-
activated protein kinase pathway. For comparison we are currently analyzing gene expression
changes in RHEK-1 cells transformed by other means. The goal of these studies is to identify com-
mon batteries of genes affected by chemical modulators of the carcinogenic process. Mechanistic
studies may allow us to correlate alterations in their expression with sequential stages in the carcino-
genic process and may aid in the risk assessment of other xenobiotics. Key words: arsenic, cDNA
microarray, cell transformation, chemical carcinogenesis, gene expression, human keratinocytes,
metal mixture, molecular markers. Environ Health Perspect 110(suppl 6):931–941 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-6/931-941bae/abstract.html
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linked to the different toxic end points. In
addition, once gene expression changes
induced by individual chemicals are identiﬁed
and linked to functional end points, interac-
tions in chemical mixtures will be substan-
tially easier to understand and predict.
We have used human keratinocytes as an
experimental model to deﬁne molecular events
that may mediate the cytotoxicity and/or car-
cinogenicity of As alone and in environmen-
tally relevant metal mixtures. We describe here
an evaluation of the transforming potential of
As alone and together with Cd, Cr, and Pb in
previously immortalized human epidermal ker-
atinocytes compared with the potent carcino-
gen N-methyl-N´-nitro-N-nitrosoguanidine
(MNNG) and negative controls. Genetic alter-
ations induced by the different chemical treat-
ments and that may be involved in their
selective toxicity and/or carcinogenicity were
analyzed by cDNA microarray technology.
Materials and Methods
Chemicals. Sodium meta-arsenite (NaAsO2),
cadmium chloride (CdCl2), chromium oxide
(CrO3), chromium chloride (CrCl3), lead
acetate [(C2H3O2)2Pb·3H2O], and dimethyl
sulfoxide (DMSO) were purchased from
Sigma Chemical Co. (St. Louis, MO,
USA). MNNG was obtained from Aldrich
(Milwaukee, WI, USA).
Cell lines and culture reagents. The
Ad12/SV40-immortalized human ker-
atinocyte cell line (RHEK-1) was obtained
from J. Rhim (Center for Prostate Disease
Research, Rockville, Maryland, USA)
(21–23). RHEK-1 was cultured in Dulbecco’s
modiﬁed Eagle’s medium supplemented with
100 U/mL penicillin, 0.1 mg/mL strepto-
mycin, 10 mM L-glutamine, and 10% fetal
bovine serum (Summit Biotechnology, Ft.
Collins, CO, USA). Methylcellulose (MC)-
based medium for determination of anchor-
age-independent growth (AIG) was obtained
as MethoCult from Stem Cell Technologies
(Vancouver, Canada).
Establishment of keratinocyte cell lines
after exposure to MNNG, As, or As-containing
mixture. RHEK-1 cells were plated at 2.5 ×
105 cells per 75-cm2 ﬂask. The conditions used
for MNNG treatment were those described by
Rhim et al. (22). Brieﬂy, 24 hr after plating,
cultures were fed with medium containing the
positive control MNNG, at 0.01 or 0.1
µg/mL, or 0.5% DMSO vehicle control. After
24 hr of exposure (one treatment only), cells
were washed with 1× phosphate-buffered
saline (PBS) and then refed with culture
medium. Cells were subsequently subcultured
weekly. RHEK-1 cells were also exposed to
low doses (9, 11, and 14 ppb) of As3+, the
metal mixture, or water vehicle controls, con-
tinuously for approximately 6 months, or 25
passages; that is, the test chemicals were added
to the culture medium at each subculturing.
The concentrations of As used corresponded to
the LD2.5, LD5, and LD10, as determined in
our laboratory for this cell type (11). The low-
mixture treatment group was composed of 1,
10, 62, and 33 ppb of As, Cr, Cd, and Pb,
respectively. In efforts to more closely mimic
the actual exposure scenario with Cr, these
chronic studies were carried out with a mixture
of 1:1 Cr3+ and Cr6+. The high-mixture treat-
ment group was exposed to 14, 104, 618, and
332 ppb of As, Cr, Cd, and Pb, respectively.
The concentrations of the four-metal mixture
used corresponded to the LD1 (low mixture)
and LD10 (high mixture) of each individual
metal in RHEK-1 cells. The resulting cultures
were designated as follows: OM1 (DMSO-
treated control cells); OM2 (0.01 µg/mL
MNNG); OM3 (0.1 µg/mL MNNG); water
control; As-Low (9 ppb As); As-Med (11 ppb
As); As-High (14 ppb As); Mix-Low (LD1
mixture); and Mix-High (LD10 mixture).
MC cloning. MC cloning as an index for
AIG was carried out every two or three pas-
sages for the cultures treated with As, metal
mixture, or MNNG. For MC cloning, 1 ×
104 cells/mL were plated in 35-mm gridded
dishes in triplicate in 1.3% MC. The number
of colonies was counted via manual inspec-
tion under phase-contrast microscopy after 2
weeks and is expressed as percentage cloning
efﬁciency.
Analysis of saturation density. Saturation
density was measured as the maximum num-
ber of cells obtained in cultures as a function
of time. Cells (1 × 104 /cm2) were plated in
25-cm2 culture ﬂasks in triplicate. Viable cells
at 5, 8, 10, 12, 15, and 17 days after initial
plating were counted by trypan blue exclu-
sion on a hemocytometer. Culture medium
was changed every 3 days. Unattached cells in
the culture medium were pelleted by centrifu-
gation and also counted.
Analysis of tumorigenicity in immuno-
compromised mice. The tumorigenicity assay
was carried out using a modiﬁcation of Rhim
et al. (22). Brieﬂy, cells from passage 16 and
passage 25 (OM1 and OM3) or passage 25
(As-Low, As-High, Mix-Low, Mix-High, and
the appropriate water controls) were collected
by 0.05% trypsin treatment. Cells (2 × 106)
in 0.1 mL PBS were injected subcutaneously
into the interscapular region of 4- to 8-week-
old male Balb/c nu/nu mice. The mice were
observed weekly for 3 months for tumor
development and growth. The tumors were
measured by caliper, excised, and fixed in
10% formalin before sectioning and slide
preparation. Tissue sections were stained with
hematoxylin and eosin and characterized by
histopathological analysis.
RNA preparation. Total RNA was iso-
lated from cultures of control and chemically
treated RHEK-1 cells (at ~70% confluence)
at passage 25 using the RNAqueous kit
(Ambion, Austin, TX, USA) and following
the manufacturer’s directions. RNA purity
and concentration were assessed by determi-
nation of absorption at 260 and 280 nm.
cDNA synthesis and radioactive labeling
for the Clontech Atlas Human Cancer 1.2
Array. Total RNA (2 µg per reaction) was
reverse transcribed from each test sample with
superscript in the presence of [α-32P]deoxy-
adenosine 5´-triphosphate (Amersham,
Piscataway, NJ, USA) using the Atlas Pure
Total RNA Labeling System (Clontech, Palo
Alto, CA, USA). Unincorporated isotope was
removed by gel ﬁltration in Chroma Spin-200
columns (Clontech). The Atlas Human
Cancer 1.2 Array was supplied by the manu-
facturer on nylon membranes; 1,185 genes
were analyzed using this array. These mem-
branes were prehybridized for 30 min at 68°C
in ExpressHyb (Clontech) containing 0.1
mg/mL sheared salmon sperm DNA. They
were then incubated with 2 × 106 cpm of radi-
olabeled cDNA probe (control OM1 or test
sample OM3; water control or test samples As-
High and Mix-High) per milliliter of
ExpressHyb buffer overnight at 68°C. After
high-stringency washes in 2× standard saline
citrate (SSC), 1% sodium dodecyl sulfate
(SDS) at 68°C, the blots were exposed to stor-
age phosphor screens (Molecular Dynamics,
Sunnyvale, CA, USA). Signals were scanned
and captured using a Storm 860 Phosphor-
imager and ImageQuant software (Molecular
Dynamics). Gene expression images were
quantified using AtlasImage 1.0 program
(Clontech) by the Atlas Technology Center.
Relative changes in gene expression were deter-
mined by normalizing the hybridization signals
to the signals obtained from all the genes
included in the array. Genes that demonstrated
≥2-fold changes in expression between control
and treatment were reported.
cDNA synthesis and fluorescent labeling
for New England Nuclear arrays. Two
microarrays from New England Nuclear
(NEN; Boston, MA, USA) were used to ana-
lyze gene expression changes in OM3 versus
OM1 and As-High and Mix-High versus the
appropriate water controls. These were the
NEN Human 2400 (2,400 genes analyzed)
and Oncogene/Tumor Suppressor (325 genes
analyzed) arrays. In addition, gene expression
in OM3 compared with OM1 was analyzed
by the NEN Kinase/Phosphatase array (275
genes analyzed); this latter analysis was not
carried out on the metal-treated cultures. We
do not, therefore, know how the genes con-
tained within this array are affected in the
metal-treated cells. Synthesis and labeling of
cDNA were carried using the MICROMAX
Direct cDNA Microarray System (NEN) fol-
lowing the manufacturer’s directions. Brieﬂy,
100 µg or 40 µg of total RNA for the Human
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2400 or Oncogene/Tumor Suppressor arrays,
respectively, was reverse transcribed from each
test sample with AMV Reverse Transcriptase
in the presence of cyanine 3 (Cy3) (for OM1
and water controls) and cyanine 5 (Cy5) (for
OM3, As-High, and Mix-High) using
MICROMAX. For the NEN Kinase/
Phosphatase array, 40 µg of RNA was used
from OM1 and OM3. Labeled cDNA from
control and treated samples was purified by
isopropyl alcohol precipitation. MICROMAX
microarray slides were used that contained the
three different arrays. The entire reaction from
the combined Cy3- and Cy5-labeled probes in
hybridization buffer (NEN) was pipetted
underneath slide coverslips. Overnight
hybridization was performed in a microarray
hybridization cassette from Corning (Corning,
NY, USA) at 65°C. After three consecutive
washes at room temperature in 0.5×
SSC/0.01% SDS, 0.06× SSC/0.01% SDS,
and 0.06× SSC, respectively, the glass slide was
placed in a 50-mL polypropylene tube and
centrifuged at 500×g for 5 min to remove
excess liquid before scanning. The slide was
scanned in a BioChip Imager (Packard,
Meriden, CT, USA). Laser and photomulti-
plier tube voltages were adjusted manually to
maximize the signal-to-noise ratio. Cy3 and
Cy5 signal intensities were standardized rela-
tive to one another by comparing the total sig-
nal intensities of all spots in each channel. The
scanner output images were quantiﬁed using
ScanAlyze (software developed by M. Eisen,
University of California at Berkeley).
Statistical analysis. One-way analysis of
variance (ANOVA) followed by Dunnett’s
test (24) was used to analyze differences
between control and chemical-treated sam-
ples in saturation density, MC cloning, and
tumorigenicity studies. p-Values < 0.05 were
considered statistically signiﬁcant.
Results
As and an As-containing metal mixture
inhibit and MNNG enhances malignant
transformation in RHEK-1 human ker-
atinocytes. To analyze the effects of As, both
alone and in metal mixtures, on malignant
transformation, we used the virally immortal-
ized human epidermal keratinocyte cell line
RHEK-1. To carry out this analysis, RHEK-1
cells were treated chronically with increasing
concentrations of either As or a mixture of As,
Cd, Cr, and Pb; this scenario was chosen to
more closely reﬂect actual human exposures.
For comparison, we also treated RHEK-1
with MNNG, a potent carcinogen that has
previously been shown to malignantly trans-
form this cell type.
With continued culture after chemical
treatment, we were able to observe substantial
changes in morphology in our RHEK-1 popu-
lations; however, these alterations were not the
same in all cultures and were not consistently
associated with malignant transformation.
Solvent control RHEK-1 cells underwent sub-
stantial morphological changes with increasing
time in culture, becoming very pleiomorphic
with distinctive nests of cobblestone-like cells
surrounded by spindlier, elongated layers of
cells. It was noteworthy, however, that at
approximately passage 13, RHEK-1 cells
treated with both the low and high concentra-
tions of MNNG began to develop foci of piled
cells from which round cells were continually
being released; these alterations were similar to
those previously described by Rhim and col-
leagues (21–23) and were not present in the
corresponding DMSO-treated OM1 cells.
With continued subculturing, in populations
treated with 0.1 µg/mL MNNG, these foci
began to dominate the entire ﬂask. By passage
16, these latter cultures consisted of substan-
tially larger cells that were relatively homoge-
neous in size and shape; this line was named
OM3. Cultures treated with 0.01 µg/mL
MNNG (OM2) also began to pile up in foci;
however, the cells in these cultures remained
small, similar to the control cells. The situation
with the As- and metal mixture–treated popu-
lations was very different from that of cells
treated with MNNG. After undergoing
chronic, long-term exposure to either As or the
metal mixture at multiple concentrations, pop-
ulations became increasingly uniform in both
size and morphology compared with the water
control cultures. The cells in the As- and mix-
ture-treated cultures were ﬂat and had a regular
polygonal epithelial appearance. This effect
was dose dependent for both As and the metal
mixture. In addition, these cultures had no pil-
ing or rounded cells, as was seen with the
MNNG-treated populations.
At passage 4 after treatment, all cultures
were analyzed biweekly for their ability to grow
in semisolid medium, that is, in an anchorage-
independent manner. As early as passage 11,
OM3 gained the AIG+ phenotype (Table 1).
The cloning efﬁciency of OM3 at passage 11
averaged 0.34% compared with 0.02% in con-
trol OM1. While working with RHEK-1, we
have observed that these cells spontaneously
become less dependent on adherence for
growth with increasing time in culture. After
25 passages we noted an increase in the AIG of
OM1; these cells formed colonies with an efﬁ-
ciency of 2.1% in MC. However, at this same
passage 25, MC cloning ability in OM3 was
approximately 19%. OM2 did not at any time
tested exhibit a signiﬁcantly higher cloning efﬁ-
ciency than OM1. In contrast to previous ﬁnd-
ings (22), treatment of RHEK-1 with the lower
concentration of MNNG (0.01 µg/mL) did
not detectably affect the malignant behavior of
the cells during the time course of our studies.
In contrast to what we observed with
MNNG-treated cells, As-High and Mix-High
cultures did not exhibit increased AIG com-
pared with water controls at any passage or
under any condition examined in our studies.
However, spontaneous progression in water
control RHEK-1 cells was quite rapid, even
compared with the progression observed in
OM1; by passage 11, the water controls exhib-
ited AIG+ growth of 1.4–1.9%. By passage 16,
these controls formed colonies in MC with
efficiencies of 1.46 and 2.63%, respectively.
Through passage 16, chronic treatment of
RHEK-1 cells with As or the metal mixture
acted in a dose-dependent manner to partially
inhibit this spontaneous acquisition of AIG+
in RHEK-1. By passage 25, however, AIG+ in
As-High and Mix-High were very similar to
water control cultures. The results of this
analysis are shown in Table 1.
Increased saturation density may be
another characteristic of malignant transforma-
tion. Thus, we measured the saturation density
of OM1, OM2, OM3, As-High, Mix-High,
and the water controls (Table 2). Interestingly,
and unexpectedly, when assayed at passage 16,
OM3 showed decreased saturation density
compared with OM1; the maximum cell den-
sities reached in these cultures were 5.7 and
3.2 × 105 cells/cm2 for OM1 and OM3,
respectively. OM2 did exhibit significantly
increased saturation density compared with
both OM1 and OM3; this phenotypic change
is likely related to the smaller size of OM2 cells
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Table 1. Anchorage-independent growth of chemically treated human RHEK-1 keratinocytes.a
Time in culture
Treatment group Passage 11 Passage 16 Passage 25
OM1 (DMSO control) 0.02 ± 0.006 0.05 ± 0.04 2.1 ± 0.21
OM2 (0.01 µg/mL MNNG) 0.03 ± 0.006 0.06 ± 0.02  3.2 ± 0.67
OM3 (0.1 µg/mL MNNG) 0.34 ± 0.04* 1.60 ± 0.22* 18.9 ± 0.66*
As control (water) 1.40 ± 0.05 1.46 ± 0.04 2.45 ± 0.03
As-Low (9 ppb) 1.41 ± 0.03 1.40 ± 0.05 2.11 ± 0.02*
As-Med (11 ppb) 0.73 ± 0.01* 1.17 ± 0.04* ND
As-High (14 ppb) 0.95 ± 0.04* 0.77 ± 0.05* 2.39 ± 0.03
Mixture control (water) 1.86 ± 0.006 2.63 ± 0.13 2.67 ± 0.10
Mix-Low (LD1)1 .42 ± 0.04* 1.49 ± 0.05* 2.51 ± 0.08
Mix-High (LD10)0 .38 ± 0.03* 0.98 ± 0.06* 2.06 ± 0.04*
ND, not determined. aMC cloning assay was carried out as described in “Materials and Methods.” Values in MC colony
formation study are expressed as mean ± SE (n = 3). *Signiﬁcantly different from control using one-way ANOVA followed
by Dunnett’s test, p < 0.05.(especially when compared with OM3) and
not to malignant transformation. We also
observed lower saturation density in RHEK-1
populations treated with the high concentra-
tions of As and the metal mixture compared
with controls; the ratios of the maximum cell
density in these cultures were 4.2:6.2 and
2.9:4.0 for As-High and Mix-High versus the
water controls, respectively.
To test the tumorigenic potential of the
chemically treated RHEK-1 cells, Balb/c nu/nu
mice were used. After subcutaneous injection
of the control and treated cell populations into
immunocompromised mice, several cultures
rapidly (within 3 weeks) and consistently
formed large dorsal tumors (Table 3). Passage
16 OM3 cells formed tumors in all injected
mice in 3 weeks. Tumors formed in mice by
passage 25 OM3 cells were signiﬁcantly larger;
the average sizes of the resulting tumors from
these time points were 6.6 mm and 10.7 mm,
respectively. At 3 weeks, in mice injected with
passage 16 OM1 cells, no tumors were
observed; however when OM1 cells were cul-
tured through 25 passages before being tested
for tumorigenicity, the results were somewhat
different. These passage 25 cells had progressed
to the point where they formed small tumors
(2.4 mm average tumors in 3 of 10 mice) by 3
weeks after injection. With both passage 16
and passage 25 OM1 cells, by 3 months after
injection tumors of approximately 6–7 mm
were observed in recipient mice, again support-
ing the hypothesis that RHEK-1 sponta-
neously progresses to a low-level malignancy
with continued time in culture. Observations
from our studies on As and the metal mix-
ture–treated cultures were not highly surpris-
ing, given the MC cloning results described
above. Neither As-High nor Mix-High cells
were tumorigenic under these conditions, even
at passage 25, when they had acquired the abil-
ity to grow in an anchorage-independent man-
ner. In contrast, by 3 weeks, both water
control cell populations formed tumors in a
portion of injected mice; cells treated with the
lower concentrations of As and the metal mix-
ture also were tumorigenic (Table 3).
Histopathological exam of excised tumors
from each culture demonstrated that they were
all poorly differentiated squamous cell carcino-
mas. Chromosome painting and karyotypic
analysis confirmed that these tumors arose
from the parental RHEK-1 cells.
Analysis of changes in gene expression that
arise during treatment of RHEK-1 cells with
MNNG, As, or the four-metal mixture. We
were interested in characterizing changes in
gene expression that may be involved in medi-
ating the different outcomes after treatment of
RHEK-1 cells with MNNG, As, or the mix-
ture of As-High, Cd or the mixture of, Cr, and
Pb-High. To explore this issue, we have begun
to use cDNA microarray technology to iden-
tify mRNA species that are over- or underex-
pressed in chemically treated versus control
cells. Our ﬁrst observation from this analysis
was that the patterns of gene expression in the
treated cultures were unique, being distinct
both from their respective controls and from
cells that were exposed to different chemicals
(Tables 4–6). Among the three chemically
treated cell populations, OM3 showed the
most numerous alterations in gene expression
(Table 4). Not only did we use an additional
array for studying OM1 and OM3, but this
ﬁnding may also be attributed in part to the
fact that MNNG is a very effective DNA-
damaging agent and mutagen and likely has
genomewide effects. In all, 72 and 41 genes
represented on the combined arrays were
induced and suppressed, respectively, in OM3
compared with OM1 cells. In As-High a total
of 52 genes were altered in their expression
compared with water controls; of these, 23
showed increased and 29 showed decreased
expression (Table 5). Last, 13 genes were
induced in the Mix-High populations, and 51
were suppressed (Table 6). A comprehensive
list of genes induced or suppressed under each
exposure scenario, along with their assigned
(putative) function, is shown in Tables 4–6.
Among the genes showing increased
expression in OM3 compared with the OM1
control population were many that could
potentially have impacts on cell proliferation,
including a) cell cycle regulators (RBQ-3,
cyclins H and A1, and CDK5); b) growth fac-
tors (int-6, irp, and PDGF2); and c) onco-
genes, several of which are involved in the
mitogen-activated protein pathway (MAP)
kinase signaling pathways, including an Erk-
3–related protein, JNK-2, PKCµ, A-raf-1, and
Net (Table 4). Additionally, genes encoding
proteins that modulate cell–cell or cell–matrix
interactions were also induced; among these
genes were macrophage inhibitory cytokine
MIC1, nerve growth factor–inducible PC4
homolog, and several protease inhibitors.
Increased expression of several tumor-associ-
ated markers, such as melanoma (A32)-associ-
ated and prostate carcinoma-associated
antigens and the adenomatus polyposis coli
(APC) protein, was consistent with the malig-
nant phenotype of OM3. Last, several proteins
involved in DNA damage response and/or
apoptosis, including p53-associated protein
and caspase 4 were expressed at higher levels in
the transformed line.
There were substantially fewer genes with
decreased expression in OM3 compared with
OM1 (Table 4). Among these genes were rep-
resentatives from several functional categories.
Particularly striking were repressions in a) mul-
tiple protein tyrosine phosphatases, including
PTP1C, PTPα, PTPσ, and receptor-type pro-
tein tyrosine phosphatase γ; b) cell-protective
mechanisms such as the ultraviolet (UV) exci-
sion repair protein RAD23A, glutathione syn-
thase, and glutathione-S-transferase (GST);
and c) integrin β4, cadherin 8, and a keratin-
related protein. Additionally, several putative
inhibitors of transformation and metastasis
such as RARRES3, suppressin, tumor suppres-
sor protein 101F6, and PCDH7 exhibited
decreased expression in OM3.
In our studies, several noteworthy genes/
gene families were altered in their expression in
As-treated cells (Table 5). In these populations,
the most striking induction was seen in DNA
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Table 2. Saturation density of chemically treated
RHEK-1 cultures.a
Saturation density
Treatment group (x 105/cm2)
OM1 (DMSO control) 5.7 ± 0.06
OM2 (0.01 µg/mL MNNG) 6.7 ± 0.06*
OM3 (0.1 µg/mL MNNG)  3.2 ± 0.09*
As control (water) 6.2 ± 0.09
As-Low (9 ppb) 4.5 ± 0.08*
As-Med (11 ppb) 4.6 ± 0.15*
As-High (14 ppb) 4.2 ± 0.07*
Mixture control (water) 4.0 ± 0.05
Mix-Low (LD1) 3.1 ± 0.17*
Mix-High (LD10) 2.9 ± 0.06*
aExperiments were conducted with passage 16 cells.
Saturation density analysis was carried out as described
in “Materials and Methods.” Values in saturation density
are expressed as mean ± SE (n = 3 ). *Signiﬁcantly differ-
ent from control using one-way ANOVA followed by
Dunnett’s test, p < 0.05.
Table 3. Tumorigenicity of MNNG-, As-, and metal mixture–treated RHEK-1 cells.a
No. with tumors/no. inoculated Average tumor size of existing 
Treatment group at week 3 tumors at week 3 (mm)b
p16 OM1 (DMSO control) 0/10 0
p16 OM3 (0.1 µg/mL MNNG) 10/10 6.6 ± 0.4*
p25 OM1 (DMSO control) 3/10 2.4 ± 0.3
p25 OM3 (0.1 µg/mL MNNG) 10/10 10.7 ± 0.4 *
p25 As control (water) 7/10 3.6 ± 0.4
p25 As-Low (9 ppb) 4/10 4.0 ± 0.4
p25 As-High (14 ppb) 1/10 1.3 ± 0.7
p25 Mixture control (water) 9/10 5.2 ± 0.6
p25 Mix-Low (LD1) 9/10 5.0 ± 0.6
p25 Mix-High (LD10) 2/10 2.2 ± 0.2*
Abbreviations: p16, passage 16 cells; p25, passage 25 cells. aThe tumorigenicity assay was performed 3 times. Data were
pooled and are represented as mean number or size of all measurable tumors. bTumor size was expressed as mean ± SE
(n = 10). *Signiﬁcantly different from corresponding control using one-way ANOVA followed by Dunnett’s test, p < 0.05.Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 6 | DECEMBER 2002 935
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Table 4. Alterations in gene expression detected by microarray analysis of MNNG-treated RHEK-1 cells.
GenBanka
accession no. Name Function Arrayb Foldc
Induction (total 72)
M74088 Adenomatous polyposis coli protein (APC protein) Tumor marker 1 4
S83171 BCL-2 binding athanogene-1 (BAG-1); glucocorticoid  Steroid receptor 1 >100
receptor–associated protein RAP46
U43746 BRCA2 Zinc ﬁnger domain 1 3
X66141 Cardiac ventricular myosin light chain 2 Filament 1 >100
U28014 Caspase-4 precursor  Apoptosis 1 5
AF011792 Cell cycle progression 2 protein  Cell cycle regulation 1 3
X66364 Cell division protein kinase 5  Cell cycle regulation 1 3
L31951 C-jun N-terminal kinase 2 (JNK2) Transcription regulation 1 49
U43901 Colon carcinoma laminin-binding protein Cancer marker 1 4
U11791 Cyclin H Cell cycle regulation 1 5
J04164 Interferon-inducible protein 9–27 Cell growth regulation 1 61
AF019770 Macrophage inhibitory cytokine 1 (MIC1) TGFβ superfamily 1 7
M28882 Melanoma-associated antigen A32; cell surface  Tumor marker 1 12
glycoprotein MUC 18
J02958 Met proto-oncogene; hepatocyte growth factor receptor precursor Protein tyrosine kinase 1 3
U39050 Mitogen-responsive phosphoprotein DOC2 Tumor suppressor from ovarian carcinoma cells 1  36
Y10313 Nerve growth factor (NGF)-inducible PC4 homolog Growth factor 1 6
U48296 PTPCAAX1 nuclear tyrosine phosphatase PRL-1 Nuclear phosphatase 1 4
X85134 RBQ-3 RB protein–binding protein 1 36
X63679 TRAM protein ER protein involved early in polypeptide translocation 1 4
X87852 Transmembrane protein sex precursor  Homology to cMET; a novel transmembrane protein 1 3
X56134 Vimentin Intermediate  ﬁlament 1 3
S65738 Actin depolymerizing factor Actin depolymerization 2 4
U29344 Breast carcinoma fatty acid synthase Involvement in breast carcinoma 2 3
M33011 (Clone GA733–2–2) carcinoma-associated antigen GA733–2 Cancer antigen from colorectal and pancreatic carcinoma 2 2
U66838 Cyclin A1 Cell cycle regulation 2 5
L37385 Homolog of mouse MAT-1 oncogene Expression in breast cancer cells 2 3
J02854 Human 20-kDa myosin light chain (MLC) 2 mRNA Smooth muscle and nonmuscle cell contractile activity 2 5
AF027205 Kunitz-type protease inhibitor  Protease inhibitor 2 3
X04741 mRNA for protein gene product 9.5 A novel cytoplasmic neuroendocrine marker protein 2 3
D78130 mRNA for squalene epoxidase Metabolism 2 3
X56160 mRNA for tenascin Extracellular matrix protein 2 3
X00699 mRNA fragment for class II histocompatibility antigen β-chain (pII-β-3) Histocompatibility antigen 2 5
M13656 Plasma protease inhibitor Protease inhibitor 2 2
U41303 Small nuclear ribonuleoprotein particle N  Pre-mRNA splicing 2 5
AF009615 ADAM10  Protumor necrosis factor α processing enzyme 3 2
M32325 Adenocarcinoma-associated antigen (KSA) Lung cell surface glycoprotein 3 3
X66087 A-myb mRNA Nuclear protein, TF 3 13
U74611 Apo-3 TNF receptor family 3 3
U14680 BRCA1 Zinc ﬁnger domain 3 3
X06182 C-kit proto-oncogene mRNA A new cell surface receptor tyrosine kinase 3 6
M12783 C-sis/platelet-derived growth factor 2 (SIS/PDGF2) Proto-oncogene 3 3
M14333 C-syn proto-oncogene Protein tyrosine kinase family 3 2
X64229 Dek mRNA Putative oncogene; gene translocation in  3 3
acute myeloid leukemia
U77085 Epithelial membrane protein  Squamous cell–associated gene 3 3
J04101 Erythroblastosis virus oncogene homolog 1 (ets-1) Proto-oncogene; TF 3 3
S82592 Evi-1, Evi-1 protein TF; overexpression in myeloid leukemia 3 4
M64240 Helix-loop-helix zipper protein (max) TF; complex with myc 3 3
O04045 hMSH2 Human mismatch repair gene 3 3
U37547 IAP homolog B  Apoptosis inhibitory protein 3 4
U62962 Int-6 GF-like proto-oncogene 3 3
AF042857 Lung cancer antigen NY-LU-12 variant A Nuclear zinc ﬁnger protein 3 3
Y18046 mRNA for FOP  FGFR1 oncogene partner 3 3
D63874 mRNA for HMG-1 Malignant transformation in gastrointestinal  3 2
adenocarcinoma
X07876 mRNA for irp protein  GF-like proto-oncogene 3 3
Z36715 mRNA for Net transcription factor A new ets TF that is activated by Ras 3 10
X03541 mRNA of trk oncogene Tyrosine kinase; a transforming gene in a  3 3
human colon carcinoma
M92424 p53-associated mRNA p53-associated gene in human sarcomas 3 2
K03199 p53 cellular tumor antigen Tumor antigen from human vulva carcinoma cell line 3 2
L78132 Prostate carcinoma tumor antigen  Tumorigenesis and metastasis 3 2
Y00705 PstI mRNA for pancreatic secretory inhibitor  Trypsin inhibitor in cancer 3 5
(expressed in neoplastic tissue)
L07868 Receptor tyrosine kinase (ERBB4) gene EGF receptor family 3 3
U16296 T-lymphoma invasion and metastasis inducing TIAM1 protein  Found in virtually all analyzed tumor cell 3 3
lines of human origin
X15187 Tra1 mRNA for homolog of murine tumor rejection antigen gp96 Cell surface glycoprotein 3 3
M76125 Tyrosine kinase receptor (axl) A transforming gene 3 4
M18391 Tyrosine kinase receptor (eph) Overexpression in several human carcinomas 3 3
M11730 Tyrosine kinase-type receptor (HER2) Oncogene 3 3
(Continued)damage response genes, including XRCC1,
RAD23A, endonuclease III homolog 1
(HNTH1), DNA repair protein MLH1, and a
heat shock protein (HSP) 40 homolog. Among
other representative inductions were genes
involved in cell cycle regulation (jun-B, FRA-1,
MTS1/p16-INK4, PCNA, early growth response
protein 1); oncogenes (EHK-1 receptor tyrosine
kinase); two putative tumor suppressor genes
(EXT1 and RDA32); and genes for proteins
regulating invasion and/or cell–cell interactions,
BMP4 and TIMP-3. Genes suppressed in As-
treated populations included those for cytopro-
tective molecules (cytosolic superoxide
dismutase [SOD], glutathione synthetase, and
glutathione-S-transferase), ICAM-1, stratum
corneum chymotryptic enzyme, MIC1, and
bikunin. In our studies, treatment with As also
was observed to inhibit expression of a variety
of cytokeratins, including 6E, 8, 13, 18, and an
unidentiﬁed 58-kDa type II protein.
The metal mixture–treated populations
had a somewhat different spectrum of gene
alterations than did cells exposed to As alone
(Table 6). Relatively few genes showed
increased expression under this exposure sce-
nario. Genes involved in cell cycle regulation
that were induced included jun-B, MTS1/p16-
INK4, FRA1, and nuclear factor 1-X. DNA
damage response/cytoprotective/apoptosis
mechanisms induced included multiple metal-
lothioneins, caspase 10, and HNTH1. Also
induced under these conditions were integrin
β4 and BMP4. In contrast, many genes were
repressed by metal mixture treatment com-
pared with control. Cell cycle regulatory pro-
teins and cytokines showing decreased
expression included WAF1/CIP1, MAPKK6,
GATA6, JNK2, TGFβ2, and mitogen-respon-
sive phosphoprotein DOC2. Many oncogenes
were suppressed, including int-1, Ret, Blym-1,
n-myc, DBL, and the EHK-1 receptor tyrosine
kinase. Among the DNA damage response/
cytoprotective/apoptosis genes showing
decreased expression were ERCC2, ERCC5,
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Table 4. (Continued)
GenBanka
accession no. Name Function Arrayb Foldc
Induction (total 72)
V00572 mRNA encoding phosphoglycerate kinase Kinase 4 2
AB011406 mRNA for alkalin phosphatase Phosphatase 4 3
X04790 mRNA for A-raf-1 oncogene Downstream signal molecule for Ras signal transduction 4 2
X75756 mRNA for protein kinase C (PKC) µ Kinase 4 2
X52192 RNA for c-fes Oncogene; protein tyrosine kinase 4 4
X59727 63-kDa protein kinase related to rat ERK3 MAP kinase signaling 4 9
Suppression (total 41)
L22253 Arginine/serine-rich splicing factor 7 mRNA splicing 1 3
U78095 Bikunin Hepatocyte GF activator inhibitor 2 1 2
L34060 Cadherin 8 Cell differentiation 1 >100
M36067 DNA ligase I DNA replication 1 3
X16707 Fos-related antigen (FRA1) AP1 1 5
U34683 Glutathione synthase Cell protection 1 2
L07515 Heterochromatin protein homolog 1 Chromatin stucture 1 13
X62534 High mobility group protein 2 Malignant transformation 1 4
X67081 Histone H4 Chromosome structure 1 4
U12255 IgG receptor FC large subunit P51 precursor Immunoglobulin structure 1 3
X53587 Integrin β4 Cell differentiation 1 6
D21063 MCM2 DNA replication licensing factor Nuclear protein 1 3
X74794 MCM4 DNA replication licensing factor Nuclear protein 1 3
U77604 Microsomal glutathione S-transferase II Cell protection 1 4
M15796 Proliferating cell nuclear antigen (PCNA) Cell cycle regulation 1 3
J03040 Secreted protein acidic and rich in cysteine precursor  Secretory protein 1 4
D21235 Ultraviolet excision repair protein RAD23A DNA repair 1 3
L47647 Creatine kinase B Kinase 2 7
S78986 Id1 (Id1-a) Inhibit transcription by forming inactive heterodimer 2 7
U68018 Mad protein homolog (hMAD-2) Downstream molecule in TGFβ receptor activation 2 3
X62570 mRNA for IFP53 IFN-inducible protein 2 9
X62571 mRNA for keratin-related protein Cell differentiation 2 3
X71635 mRNA for neuropeptide Y-like receptor G protein coupled receptor 2 5
AJ222700 mRNA for TSC-22 protein TGFβ-stimulated clone 22; apoptosis 2 4
U51478 Sodium/potassium-transporting ATPase β3 subunit Ion transporter 2 5
AF007165 Suppressin  A novel suppressor of cell cycle entry 2 3
U49436 Translation initiation factor 5  Gene transcription/ translation 2 5
L25610 Cyclin-dependent kinase inhibitor; p21CIP1 Cdk-interacting protein 3 6
AF027964 MAD-related protein Smad2 Downstream molecule in TGFβ receptor activation 3 4
D28124 mRNA for unknown product; putative  Putative tumor suppressor 3 2
neuroblastoma tumor suppressor gene
U46691 Putative chromatin structure regulator  Transcriptional regulation 3 2
AF040704 Putative tumor suppressor protein 101F6 Putative tumor suppressor 3 2
AF060228 Retinoic acid receptor responder 3 (RARRES3) Retinoid-induced class II tumor suppressor 3 7
X75208 HEK2 mRNA for protein tyrosine kinase receptor Protein tyrosine kinase receptor 4 3
AB006757 mRNA for PCDH7  Metastasis inhibitor 4 5
U48959 MLC kinase Kinase 4 4
M34668 Protein tyrosine phosphatase (PTPase-α) mRNA Phosphatase 4 2
U40317 Protein tyrosine phosphatase (PTPase-σ) Phosphatase 4 2
X62055 PTP1C mRNA for protein-tyrosine phosphatase 1C Phosphatase 4 2
L09247 Receptor-type protein tyrosine phosphatase γ Phosphatase 4 2
AF099989 Ste-20 related kinase SPAK Kinase 4 2
Abbreviations: EGF, epidermal growth factor; ER, endoplasmic reticulum; FC, crystallizable fragment of an immunoglobin. FGFR, ﬁbroblast growth factor receptor; GF, growth factor; IFN,
interferon; RB, retinoblastoma; TF, transcription factor; TNF, tumor neurosis factor. aGene accession numbers are from the GenBank database (http://www.ncbi.nlm.nih.gov/genbank/gen-
bankoverview.html). b1, Clontech Cancer 1.2; 2, NEN Human 2400; 3, NEN Oncogene/Tumor Suppressor; 4, NEN Kinase/Phosphatase array. cValues are represented as mean from two
experiments for arrays 2, 3, and 4 in chemically treated cell population.MSH2, TDG, cytosolic SOD, and catalase.
Many additional kinases/phosphatases were
altered in their expression, including an ERK3-
related protein kinase, HCK, several creatine
kinases, HYL, and PRL-1.
Detailed analysis of data from OM3, As-
High, and Mix-High demonstrated that, in
addition to numerous chemical-speciﬁc gene
changes, several genes were altered in a simi-
lar or opposite manner under the different
exposure conditions (Table 7). There were no
genes commonly induced by MNNG and As
or the metal mixture, although the RARRES3
gene (a retinoid-induced tumor suppressor)
was suppressed under all three treatment con-
ditions. As and metal mixture treatment did
increase expression of a common group of
genes, including JunB, FRA1, MTS1, and a
member of the TGFβ family, BMP4 (25,26).
These two exposures also commonly sup-
pressed expression of tumor antigen L6,
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Table 5. Alterations in gene expression detected by microarray analysis of As-treated RHEK-1 cells.
GenBanka
accession no. Name Function Arrayb Foldc
Induction (total 23)
M63959 α2-Macroglobulin receptor–associated Human homolog of a Heymann nephritis antigen  1 2
protein precursor (α2-MRAP)
D30751 Bone morphogenetic protein 4 (BMP4)  Production of skeletal structure during development;  1 5
TGFβ family
L27211 Cyclin-dependent kinase 4 inhibitor (CDK4I);  Cell cycle regulation 1 2
multiple tumor suppressor 1 (MTS1); p16-INK4
U07418 DNA mismatch repair protein MLH1; COCA2 DNA repair 1 4
M36089 DNA-repair protein XRCC1 DNA repair 1 4
X52541 Early growth response protein 1 (hEGR1) TF 1 2
X79067 EGF response factor 1  Early response gene 1 6
U79718 Endonuclease III homolog 1 (HNTH1) DNA repair 1 2
X16707 FRA1 AP1 1 3
M29039 Jun-B AP1 1 3
M15796 PCNA Cell cycle regulation 1 3
D21235 UV excision repair protein RAD23A DNA repair 1 6
S79639 EXT1, putative tumor suppressor/hereditary  Putative tumor suppressor 2 3
multiple exostoses candidate gene
M96803 General β-spectrin  Membrane skeleton protein 2 3
U40992 HSP 40 homolog Cell protection 2 3
X95425 mRNA for EHK-1 receptor tyrosine kinase Receptor tyrosine kinase; formation of neuronal pathway 2 4
AB000220 mRNA for semaphorin E Non-MDR drug resistance gene 2 5
U14394 Tissue inhibitor of metalloproteinases-3 (TIMP-3) Metalloprotease inhibitor 2 9
M19154 TGFβ2 TGFβ superfamily 2 3
M95787 22-kDa smooth muscle protein  Structural protein 2 3
L04288 Cyclophilin-related protein Function of natural killer cells 3 3
M98833 ERGB transcription factor; FLI-1 homolog A new Ets TF 3 6
AF061836 Putative tumor suppressor protein RDA32 Putative tumor suppressor 3 6
Suppression (total 29)
U78095 Bikunin HGF activator inhibitor 1 7
M34225 Cytokeratin 8 (K8) Cell differentiation 1 3
M26326 Cytokeratin 18 (K18) Cell differentiation 1 3
K00065 Cytosolic superoxide dismutase 1 (SOD1) Cell protection 1 4
U34683 Glutathione synthase Cell protection 1 7
U90313 Glutathione S-transferase homolog Cell protection 1 3
AF019770 MIC1 TGFβ superfamily 1 35
L33930 CD24 signal transducer and 3´ region A potential early tumor marker in  2 18
human hepatocellular carcinoma
M77830 Desmoplakin I Cell surface attachment site for  2 8
cytoplasmic intermediate ﬁlaments
M20681 Glucose transporter-like protein-III (GLUT3) Expression in fetal skeletal muscle 2 3
AB000712 hCPE-R mRNA for Clostridium perfringens enterotoxin (CPE) receptor CPE receptor 2 6
X58072 hGATA3 mRNA for trans-acting T-cell speciﬁc transcription factor TF 2 6
L42611 Keratin 6 isoform (K6e) Cell differentiation 2 3
M26512 Keratin 8 mRNA, 5´ end Cell differentiation 2 4
M21389 Keratin type II (58 kDa) Cell differentiation 2 3
X52426 mRNA for cytokeratin 13 Cell differentiation 2 5
X00497 mRNA for HLA-DR antigens associated invariant chain p33 Transmembrane polarity 2 10
X06990 mRNA for intercellular adhesion molecule (ICAM)-1  Cell adhesion molecule 2 2
X69549 mRNA for rho GDP-dissociation inhibitor 2 Inhibit GTP binding; disruption of actin cytoskeleton 2 3
L41351 Prostasin Prostate-speciﬁc marker 2 5
L33404 Stratum corneum chymotryptic enzyme Serine protease 2 15
M73554 Bcl-1 Anti-apoptosis 3 3
U66894 Epithelium-restricted Ets protein ESX Oncogene; TF 3 4
X51602 Flt mRNA for receptor-related tyrosine kinase Fms-related tyrosine kinase 3 6
M32325 KSA Lung cell surface glycoprotein 3 4
Z13009 mRNA for E-cadherin Invasion suppressor; Ca-dependent cell adhesion molecule  3 6
AF060228 RARRES3 Retinoid-induced class II tumor suppressor 3 4
AF070675 TNF-inducible protein CG12–1 Vascular endothelial gene 3 4
M90657 Tumor antigen L6 Tumor-associated cell surface antigen 3 3
Abbreviations: GDP, guanosine diphosphate; HGF, hepatocyte growth factor; MDR, multiple drug resistance protein/gene. aGene accession numbers are from the GenBank database
(http://www.ncbi.nlm.nih.gov/genbank/genbankoverview.html). b1, Clontech Cancer 1.2; 2, NEN Human 2400; 3, NEN Oncogene/Tumor Suppressor; 4, NEN Kinase/Phosphatase array. cValues
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Table 6. Alterations in gene expression detected by microarray analysis of mixture-treated RHEK-1 cells.a
GenBankb
accession no. Name Function Arrayc Foldd
Induction (total 13)
M63959 α-2-MRAP Human homolog of a Heymann nephritis antigen 1 3
D30751 BMP 4 TGFβ family 1 4
U60519 Caspase-10 precursor  Apoptosis 1 4
M34570 Collagen 6 α 2 subunit  Structural protein 1 5
U79718 HNTH1 DNA repair 1 2
X16707 FRA1 AP1 1 4
D13365 Growth inhibitory factor; metallothionein-III (MT-III) Cell growth regulation 1 3
X53587 Integrin β4 Cell  differentiation 1 2
M29039 Jun-B AP1 1 2
L27211 MTS1; CDK4I; p16-INK4 Cell cycle regulation 1 3
U90551 Histone 2A-like protein  Nuclear protein 2 3
X76717 MT-1l mRNA Cell protection 2 3
L31881 Nuclear factor I-X Interference with transcriptional activation 2 3
Suppression (total 51)
S83171 BAG-1 Steroid receptor 1 8
U09579 Cyclin-dependent kinase inhibitor 1; WAF1/CIP1 Cell cycle regulation 1 6
X52221 DNA excision repair protein ERCC2 DNA repair 1 11
L20046 DNA excision repair protein ERCC5 DNA repair 1 2
U04045 DNA mismatch repair protein MSH2 DNA repair 1 4
U39657 Dual-speciﬁcity mitogen-activated protein kinase  MAP kinase signaling 1 23
kinase 6 (MAPKK 6)
U51166 G/T mismatch-speciﬁc thymine DNA glycosylase (TDG) DNA repair 1 2
L31951 JNK2 Transcription regulation 1 3
AF019770 MIC1 TGFβ superfamily 1 7
U53446 Mitogen-responsive phosphoprotein DOC2 Tumor suppressor from ovarian carcinoma cells  1 4
U48296 PTPCAAX1 nuclear tyrosine phosphatase PRL-1 Nuclear phosphatase 1 8
K00065 SOD1 Cell protection 1 3
X85960 Trk-T3 oncoprotein Oncogene; tyrosine kinase 1 6
X56134 Vimentin Intermediate  ﬁlament 1 4
AF047347 Adaptor protein X11α Slows cellular amyloid precursor protein processing  2 4
and reduces Aβ40 and Aβ42 secretion
M22489 BMP-2A TGFβ family 2 6
L47647 Creatine kinase B Kinase 2 5
M14780 Creatine kinase M Kinase 2 5
M81635 Erythrocyte membrane protein Cation transporter inhibitor 2 4
M20681 GLUT3 Expression in fetal skeletal muscle 2 19
M97796 Helix-loop-helix protein Id-2 Nuclear protein; expression in early development 2 3
X77278 HYL tyrosine kinase mRNA Nonreceptor protein tyrosine kinase 2 3
S78986 Id1; Id1-a transcription regulator; helix-loop-helix protein 2 6
X04076 Kidney mRNA for catalase Cell protection 2 4
X95425 mRNA for EHK-1 receptor tyrosine kinase Formation of neuronal pathway 2 3
D87811 mRNA for GATA-6 TF 2 4
X71635 mRNA for neuropeptide Y-like receptor G protein-coupled receptor 2 9
Y10032 mRNA for putative serine/threonine protein kinase Kinase 2 4
X92494 mRNA for STM-7 protein A novel phosphatidyl inosine-4-phosphate-5-kinase 2 5
S75725 Prostacyclin-stimulating factor PGI2-stimulating factor from ﬁbroblast cells 2 6
X59727 63 kDa protein kinase related to rat ERK3 MAP kinase signaling 2 4
U49857 Transcriptional activator Nuclear protein 2 3
M19154 Transforming growth factor β2 TGFβ superfamily 2 4
M90657 Tumor antigen L6 Tumor-associated cell surface antigen 2 15
U57059 Apo-2 ligand TNF receptor family 3 7
K01884 Blym-1 transforming gene Transforming gene 3 6
M62397 Colorectal mutant cancer protein. Cancer marker 3 5
J03639 DBL oncogene encoding a transforming protein Transforming oncogene 3 28
M34309 Epidermal growth factor receptor  GF receptor 3 3
Y00664 Germ line n-myc gene TF 3 8
M16591 Hemopoietic cell protein-tyrosine kinase gene (HCK),  Protein tyrosine kinase 3 5
clone λ-a2/1a
X03072 Int-1 mammary oncogene GF-like proto-oncogene 3 5
X07384 mRNA for GLI protein Oncogene; zinc ﬁnger protein 3 5
X87241 mRNA for hFat protein Cadherin superfamily 3 4
X07876 mRNA for irp protein  GF-like proto-oncogene 3 4
Y00705 PstI mRNA for pancreatic secretory inhibitor  Trypsin inhibitor in cancer 3 4
AF069072 Putative lung tumor suppressor DAL1 Putative tumor suppressor 3 10
AF060228 RARRES 3 Retinoid-induced class II tumor suppressor 3 6
M57464 Ret proto-oncogene Oncogene; tyrosine kinase 3 7
AF016028 Sarcospan-2  25-kDa Transmembrane component of dystrophin  3 3
glycoprotein complex
M55994 Tumor necrosis factor receptor II (TNFrII) TNF receptor family 3 8
aMicroarray analysis was carried out using the Clontech Cancer 1.2, NEN Human 2400, and NEN Oncogene/Tumor Suppressor arrays for all samples. NEN Kinase/Phosphatase array
was analyzed for MNNG-treated cells only. bGene accession numbers are from the GenBank database (http://www.ncbi.nlm.nih.gov/genbank/genbankoverview.html). c1, Clontech Cancer
1.2; 2, NEN Human 2400; 3, NEN Oncogene/Tumor Suppressor; 4, NEN Kinase/Phosphatase array.dValues are represented as mean from two experiments for arrays 2, 3, and 4 in chemi-
cally treated cell population.SOD1, and MIC1, another member of the
TGFβ family. Interestingly, the largest group
of genes was those oppositely regulated by
MNNG and the metal mixture, among
which were JNK2, ERK3, nuclear phosphatase
PRL-1, an unidentified Ser/Thr protein
kinase, integrin β4, and vimentin.
Discussion
To develop more efﬁcient methodologies for
evaluating carcinogenic potentials for environ-
mentally relevant chemicals such as As and
other metals, we have attempted to identify
molecular markers involved in the process of
carcinogenesis in keratinocytes. In our studies,
the Ad12/SV40-immortalized human epider-
mal keratinocyte cell line RHEK-1 slowly and
spontaneously progressed to a malignant phe-
notype with continued passage. Progression of
RHEK-1 was enhanced greatly by treatment
of the cells with the strong initiating agent
MNNG. In contrast, treatment of RHEK-1
with DMSO, As alone, or As in the presence
of Cd, Cr, or Pb acted to inhibit this progres-
sion. Microarray analysis allowed us to catalog
widespread changes in gene expression in
treated cells that may potentially correlate
with these different toxicological end points.
Several investigators have taken advantage
of the SV40 virus in development of immor-
talized and/or “transformed” cell lines from
normal primary tissues (27–29). These stud-
ies have described a variety of phenotypic
changes frequently associated with expression
of viral T antigens in infected cultures,
including increased cloning efficiency and
proliferative potential, unlimited life span in
culture, and anchorage- and/or growth fac-
tor–independent growth. In these studies,
clones surviving “crisis” are highly variable in
their growth properties initially and change
fairly rapidly with increasing time in culture
(27,30). Transformation by SV40 appears to
progress over time, with acquisition of AIG+
and tumorigenicity occurring spontaneously
in some cell lines. In our studies, RHEK-1
progressed to the AIG+ or tumorigenic phe-
notype at vastly different rates depending on
the chemical treatment the cells received.
Although this phenomenon may have been
due to either genetic or epigenetic mecha-
nisms, depending on the chemical, specific
alterations in gene expression are, without
doubt, involved.
In studies such as these, where large num-
bers of genes are identiﬁed and assignment of
a mechanistic role to speciﬁc gene changes is
the desired goal, it is the analysis and interpre-
tation of data that become difficult. In our
studies, we need to compare not only each
chemically treated RHEK-1 line with its
appropriate control, but also gene expression
changes in cells treated with transformation-
enhancing (MNNG) versus transformation-
inhibitory (As and the metal mixture)
chemicals. To further complicate the picture,
genes altered in their expression after treatment
of cells with potentially carcinogenic agents
likely fall into at least two categories. The ﬁrst
would be genes directly involved in or mediat-
ing some aspect of malignant transformation,
that is, genes whose function or lack thereof is
necessary for neoplastic progression. The sec-
ond group would be composed of genes that
are altered as a result of cytotoxic stress on the
cell and are not involved in the malignant phe-
notype at all. As a first approach, analysis of
the known or putative functions of identiﬁed
genes may yield some insight into their poten-
tial roles in the toxicological end point of inter-
est, that is, transformation or toxicity.
From the alterations in gene expression
that we observed in our studies, one could
formulate several interesting hypotheses
concerning transformation-specific effects
on RHEK-1. More rapid conversion of this
keratinocyte cell line to the tumorigenic
phenotype by MNNG could potentially be
mediated by constitutively increased expres-
sion of growth factors and/or oncogenes
such as PDGF, members of the MAP kinase
signaling pathway, and/or the cyclins or
cyclin-dependent kinases. Activation of the
MAP kinase pathway is the primary
response to mitogenic stimuli in all cell
types (31). Multiple genes involved in this
pathway were selectively induced in
MNNG-transformed cells compared with
As- and metal-mixture–treated populations.
In Mix-High populations, which were non-
tumorigenic, the JNK2, the ERK3 homolog,
and MAPKK6 genes demonstrated substan-
tially decreased expression compared with
water controls; these findings are consistent
with a role for activation of the MAP kinase
pathway in progression of RHEK-1. One
can also speculate that altered expression of
a host of protein phosphatases in a cell,
such as was observed in OM3, would have
profound impacts on its proliferative poten-
tial and facilitate its ultimate transforma-
tion. Protein phosphatases are crucial players
in regulation of the mitogenic cascade,
among other functions, and changes in their
expression have been strongly linked to car-
cinogenesis in many studies (32). Because
malignant transformation is a multistep, and
very complex, process, it is likely that many
of the alterations in gene expression that we
detected (as well as others) are involved.
Rhim et al. (21,22) and Yang et al. (23)
have been able to derive multiple malignant
lines from RHEK-1 by treating the cells with
chemicals such as MNNG, 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD), and
4-nitroquinoline-1-oxide (4NQO), exposing
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Table 7. Genes altered in their expression by multiple chemical treatments.
Treatment
As/Mix/MNNG As/MNNG Mix/MNNG As/Mix
Genes commonly  JunB
induced by treatment FRA1
MTS1
Endonuclease III homolog 1 (HNTH1)
BMP4
α-2-MRAP
Genes commonly 
suppressed by treatment RARRES3 GSH synthase B Creatine kinase Tumor antigen L6
Bikunin Id1-a SOD1
mRNA for neuropeptide Y-like receptor MIC1
GLUT3
Opposite regulation MIC1 (⇓⇓⇑) KSA (⇓⇑) JNK2 (⇓⇑) TGFβ2 (⇑⇓)
by treatment FRA1 (⇑⇑⇓) RAD23A (⇑⇓) ERK3 (⇓⇑) mRNA for EHK-1 receptor tyrosine kinase (⇑⇓)
PCNA (⇑⇓) DOC2 (⇓⇑)
Nuclear tyrosine phosphatase (PRL-1) (⇓⇑)
mRNA for irp protein (⇓⇑)
BAG-1 (⇓⇑)
Vimentin (⇓⇑)
Pancreatic secretory inhibitor (⇓⇑)
Integrin β4 (⇑⇓)them to X ray, and transfecting them with
oncogenic viruses. In collaborative studies
with these investigators, we will compare gene
expression patterns in these various lines with
OM1 and OM3; the primary goal here
would be to identify, if there is one, a com-
mon battery of genes altered during progres-
sive transformation of RHEK-1 by multiple
chemical and physical agents. Having several
transformed lines with the same basic wild-
type background of gene expression should
greatly facilitate our identification of genes
potentially involved in malignant progression
of this cell type. Our results from these stud-
ies could then be tested with other cell types
transformed by various means.
Many types of studies, both epidemiolog-
ical and in the laboratory, have demonstrated
that most, if not all, of the metals used in our
work are human carcinogens. However, in
our hands, both As and the As-containing
metal mixture were inhibitory to malignant
progression of RHEK-1. This is not the ﬁrst
demonstration of an “anticarcinogenic” effect
of As; the metal has been shown to inhibit
formation of GST-P–positive hepatic foci in
chemically treated rats in vivo and is currently
being used in chemotherapeutic regimens for
acute promyelocytic leukemia (33–36).
Although the mechanism of arsenic trioxide’s
clinical effects remain unclear, it has been
shown to induce apoptosis in leukemic and
lymphoid cell lines in vitro (35,36). The
observed changes in gene expression after
exposure to As alone were not inconsistent
with an anticarcinogenic effect and indicated
that the metal generally stimulated DNA-
protective mechanisms in exposed cells.
Particularly interesting was the strong induc-
tion of multiple DNA repair proteins, includ-
ing XRCC1, HNTH1, RAD23A, and
MLH1, in the As-High populations, which
may be a function of the clastogenic and/or
comutagenic effects of the metal (37–44).
Induction by As of multiple regulators of the
cell cycle (jun-B, c-fos/FRA-1, and EGR1)
has also been seen in other studies where it is
assumed that the metal is acting to promote
carcinogenesis (45,46). Obviously, given the
complexity of the cell, it is highly likely that
the carcinogenic or anticarcinogenic effect of
the metal in any one situation or cell type is
dependent on batteries of genes working
together and not any single gene change.
Because the metal mixture also acted to
inhibit transformation of RHEK-1 in our
studies, common gene expression changes
seen in both As-High and Mix-High cells
may be important in the process and worth
exploring in more detail. 
Alterations in gene expression that differ
depending on whether As is alone or mixed
with other metals are also highly interesting
and may potentially help us to understand
the dose-dependent metal–metal interactions
we have observed in these cells in other short-
term cytotoxicity studies in the lab (11,47).
For example, in contrast to the situation in
As-High, only one of the same DNA repair
genes, HNTH1, was induced in cells treated
with the As-containing metal mixture, despite
the fact that the concentration of As was the
same in both cultures. In fact, we identified
four DNA repair proteins in this latter popu-
lation that were suppressed, likely by one of
the other metals in the mixture. In addition,
two metallothionein genes showed increased
expression in Mix-High, certainly a result of
the presence of Cd in the mix; cells treated
with As alone did not exhibit increased
expression of these important cytoprotective
molecules and, in fact, showed decreased glu-
tathione synthase and GST levels. Certainly,
these ﬁndings have implications for the cyto-
toxicity of the metals alone and together in
simple or complex mixtures.
In conclusion, we have used DNA
microarray analysis to identify changes in
gene expression in the human keratinocyte
cell line RHEK-1 in response to treatment
with chemicals that enhance or inhibit its
spontaneous malignant transformation. Our
studies have shown unique and intriguing
gene expression patterns in cells treated with
either As, an As-containing chemical mix-
ture, or the potent mutagen MNNG.
Meticulous analysis of gene expression pat-
terns in a variety of cell types, as described
above, and timewise comparison of defined
changes with acquisition of transformation-
associated characteristics such as AIG and
tumorigenicity should allow us to identify
potential players in each step of the process
of malignant conversion. In future studies,
these “transformation-associated” molecular
markers will be used in biologically based
dose–response models to predict the car-
cinogenic potentials of other xenobiotics.
Additionally, once we have a clear mechanis-
tic understanding of how single carcinogenic
agents work and have been able to model
the process using computational techniques,
chemical mixtures will be much more
amenable to study. Linkage of models
through common metabolic pathways
and/or mechanisms of cytotoxicity will allow
a more comprehensive view of the potential
health/carcinogenic effects of complex
chemical mixtures.
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